LumiThera raises $14M to complete LIGHTSITE III trial and pursue U.S. clearance for Valeda
LumiThera, a Poulsbo, Wash. medical device startup, raised $14 million to finish enrollment in its LIGHTSITE III U.S. trial and seek U.S. regulatory clearance for Valeda, a photobiomodulation device for dry age-related macular degeneration already approved in the EU.
No comments yet.